Protecting the patient in value-based pricing schemes

Area of Science:

• Health economics
• Pharmaceutical policy
• Personalized medicine

Background:

• Patient response heterogeneity necessitates new drug pricing policies.
• Uniform drug pricing fails to account for varying health benefits across indications.
• Current pricing mechanisms may lead to reduced drug availability for specific patient groups.

Purpose of the Study:

• To establish a framework for comparing diverse drug pricing policies.
• To analyze pricing strategies in the context of patient and indication heterogeneity.

Main Methods:

• Narrative review of existing drug pricing frameworks.
• Comparative analysis of indication value-based prices (IBP) and performance-based pricing schemes.

Main Results:

• Indication value-based prices (IBP) can be superior for verifiable heterogeneity but may restrict access and are difficult to implement.
• Performance-based pricing is sub-optimal with unverifiable characteristics, often hindered by complexity, high administrative costs, and information asymmetry.
• Real-world evidence indicates significant practical limitations for performance-based pricing.

Conclusions:

• Personalized medicine presents pricing challenges, with performance-based prices potentially limiting drug availability.
• Regulators must promote transparency and develop multi-indication pricing models, like blended agreements, to safeguard patient access.
• Strategic pricing requires careful consideration of heterogeneity to balance innovation, access, and economic viability.